409 related articles for article (PubMed ID: 28087980)
21. Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma.
Kawaida M; Yamazaki K; Tsujikawa H; Fukuma M; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Pathol Int; 2019 Mar; 69(3):125-134. PubMed ID: 30729617
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
23. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.
Wang YL; Zhu ZJ; Teng DH; Yao Z; Gao W; Shen ZY
World J Gastroenterol; 2012 May; 18(19):2408-14. PubMed ID: 22654434
[TBL] [Abstract][Full Text] [Related]
24. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
Du JL; Wang YL; Shi HY; Guo AT; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
[TBL] [Abstract][Full Text] [Related]
25. Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma.
Hass HG; Jobst J; Scheurlen M; Vogel U; Nehls O
Anticancer Res; 2015 Apr; 35(4):2021-8. PubMed ID: 25862856
[TBL] [Abstract][Full Text] [Related]
26. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
[TBL] [Abstract][Full Text] [Related]
27. Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression.
Wang B; Xian J; Zang J; Xiao L; Li Y; Sha M; Shen M
Biochem Biophys Res Commun; 2019 Jan; 509(1):143-147. PubMed ID: 30573358
[TBL] [Abstract][Full Text] [Related]
28. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells.
Qi XH; Wu D; Cui HX; Ma N; Su J; Wang YT; Jiang YH
Mol Med Rep; 2014 Dec; 10(6):3177-84. PubMed ID: 25270552
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
30. A new membrane re-anchored protein originating from GPC3 against hepatoma cells HepG2.
Yang D; Yang J; Lu F; Li C; Yang J; Liang J
Mol Med Rep; 2011; 4(6):1067-73. PubMed ID: 21904776
[TBL] [Abstract][Full Text] [Related]
31. Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma.
Luan F; Liu B; Zhang J; Cheng S; Zhang B; Wang Y
Pathol Res Pract; 2017 Sep; 213(9):1037-1042. PubMed ID: 28869105
[TBL] [Abstract][Full Text] [Related]
32. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.
Hagag NA; Ali YBM; Elsharawy AA; Talaat RM
J Gastrointest Cancer; 2020 Mar; 51(1):234-241. PubMed ID: 31028536
[TBL] [Abstract][Full Text] [Related]
33. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
Li J; Gao JZ; Du JL; Wei LX
World J Gastroenterol; 2014 May; 20(20):6336-44. PubMed ID: 24876756
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma.
Dhungel B; Andrzejewski S; Jayachandran A; Shrestha R; Ramlogan-Steel CA; Layton CJ; Steel JC
Gene Ther; 2018 Apr; 25(2):115-128. PubMed ID: 29563582
[TBL] [Abstract][Full Text] [Related]
37. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
38. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
40. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients.
Ning S; Bin C; Na H; Peng S; Yi D; Xiang-hua Y; Fang-yin Z; Da-yong Z; Rong-cheng L
Mol Biol Rep; 2012 Jan; 39(1):351-7. PubMed ID: 21655958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
